Go Deep
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 16,601 | 31.8 | 6.22 | 1.17 | 29,151.35 |
| Oct 2026 | 16,338 | 32.8 | 6.41 | 1.17 | 29,787.75 |
| Oct 2026 | 17,118 | 32.0 | 6.25 | 1.17 | 28,906.29 |
| Oct 2026 | 17,337 | 31.1 | 6.08 | 1.17 | 28,008.56 |
| Oct 2026 | 17,246 | 32.4 | 6.15 | 1.17 | 28,345.87 |
| Oct 2026 | 17,323 | 31.1 | 6.09 | 1.17 | 27,992.06 |
| Oct 2026 | 17,279 | 31.3 | 6.12 | 1.17 | 28,187.02 |
| Oct 2026 | 17,044 | 32.3 | 6.31 | 1.17 | 29,051.74 |
| Oct 2026 | 16,829 | 33.2 | 6.49 | 1.17 | 29,772.58 |
| Oct 2026 | 17,008 | 32.4 | 6.34 | 1.17 | 29,055.38 |
Ligand Pharmaceuticals Incorporated Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 63,693,000.0 | 51,722,000.0 | 59,666,000.0 | 115,461,000.0 |
| Net Profit | 48,508,000.0 | -13,345,000.0 | 44,784,000.0 | 117,273,000.0 |
| EPS | 2.4 | -0.7 | 2.3 | 6.0 |
Ligand Pharmaceuticals Incorporated Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 268,087,000.0 | 167,133,000.0 | 131,314,000.0 | 196,245,000.0 | — |
| Net Profit | 124,453,000.0 | -4,032,000.0 | 52,154,000.0 | -33,361,000.0 | — |
| EPS | 6.4 | -0.2 | 3.0 | -2.0 | — |
Ligand Pharmaceuticals Incorporated Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,560,637,000.0 | 941,774,000.0 | 787,216,000.0 | 762,668,000.0 | — |
| Total Liabilities | 543,425,000.0 | 111,335,000.0 | 86,303,000.0 | 165,183,000.0 | — |
| Total Equity | 1,017,212,000.0 | 830,439,000.0 | 700,913,000.0 | 597,485,000.0 | — |
Owes vs Owns
Ligand Pharmaceuticals Incorporated owed $0.56 for every $1 it owned in Jun 2026, up from $0.22 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.56× | 0.35× | 0.12× | 0.11× | 0.22× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ligand Pharmaceuticals Incorporated Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 48.5%Receivables 3.9%Inventory 0.6%Fixed assets (tangible) 0.7%Intangible assets 21.0%Long-term investments 23.4%Other assets 2.0%
How it's funded — Dec 2025
Long-term debt 28.6%Other liabilities 6.0%Shareholders' equity 65.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 756.3 | 266.2 | 170.3 | 211.9 |
| Receivables | 61.0 | 42.4 | 39.3 | 35.0 |
| Inventory | 9.1 | 14.1 | 24.0 | 13.3 |
| Fixed assets (tangible) | 10.8 | 24.8 | 25.1 | 27.5 |
| Intangible assets | 327.0 | 371.9 | 403.0 | 458.3 |
| Long-term investments | 364.8 | 195.9 | 111.6 | 3.0 |
| Other assets | 31.6 | 26.4 | 14.0 | 13.7 |
| Liabilities & equity | ||||
| Short-term debt | 1.1 | 1.3 | 0.4 | 76.7 |
| Long-term debt | 446.2 | 5.8 | 5.8 | 10.3 |
| Payables | 3.2 | 5.2 | 2.4 | 5.3 |
| Other liabilities | 92.9 | 99.0 | 77.7 | 72.8 |
| Shareholders' equity | 1,017.2 | 830.4 | 700.9 | 597.5 |
| Net tangible assets | 690.2 | 458.5 | 297.9 | 139.2 |
Ligand Pharmaceuticals Incorporated Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 49,359,000.0 | 97,047,000.0 | 49,577,000.0 | 137,850,000.0 | — |
| Investing Activities | -377,322,000.0 | -143,664,000.0 | -11,682,000.0 | 163,624,000.0 | — |
| Financing Activities | 428,223,000.0 | 97,141,000.0 | -59,947,000.0 | -275,990,000.0 | — |